Apyx Medical's (APYX) Sell (E+) Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "sell (E+)" rating for Apyx Medical (NASDAQ:APYX) based on its recent research note to investors.
• Apyx Medical reported a negative net margin of 37.11% and had earnings per share (EPS) of ($0.09), meeting consensus estimates.
• Institutional investors own 55.33% of Apyx Medical's stock, with several firms making new acquisitions in the company recently.

Apyx Medical (NASDAQ:APYX - Get Free Report)'s stock had its "sell (e+)" rating restated by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Apyx Medical Stock Performance

Shares of APYX traded up $0.03 during trading hours on Wednesday, hitting $2.87. The stock had a trading volume of 145,078 shares, compared to its average volume of 108,534. The company has a debt-to-equity ratio of 4.61, a quick ratio of 3.95 and a current ratio of 4.72. The firm has a 50-day moving average price of $2.10 and a 200 day moving average price of $1.76. Apyx Medical has a fifty-two week low of $0.76 and a fifty-two week high of $2.99. The firm has a market capitalization of $108.54 million, a price-to-earnings ratio of -6.38 and a beta of 1.46.

Apyx Medical (NASDAQ:APYX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Apyx Medical had a negative net margin of 37.11% and a negative return on equity of 158.22%. The firm had revenue of $11.37 million during the quarter, compared to analysts' expectations of $11.69 million. Apyx Medical has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Apyx Medical will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Fisher Asset Management LLC acquired a new position in Apyx Medical in the second quarter valued at about $34,000. Strategic Advisors LLC purchased a new position in shares of Apyx Medical in the first quarter valued at approximately $27,000. Joel Isaacson & Co. LLC purchased a new position in shares of Apyx Medical in the first quarter valued at approximately $28,000. Osaic Holdings Inc. purchased a new position in shares of Apyx Medical in the second quarter valued at approximately $50,000. Finally, Salem Investment Counselors Inc. purchased a new position in shares of Apyx Medical in the third quarter valued at approximately $97,000. Institutional investors and hedge funds own 55.33% of the company's stock.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.